Cardiac Outcomes Studies For Diabetes Drugs Pose Trial Design Challenges
Executive Summary
Although FDA's Endocrinologic and Metabolic Drugs Advisory Committee is calling for large, pre-approval safety trials to detect cardiovascular risk for diabetes drugs, the panel noted that conducting those trials are fraught with confounding variables